AIM Vaccine Co., Ltd.
Research AIM Vaccine Co., Ltd. (6660.HK) on Bullrun: market cap HKD 1.93B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6660.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 1.93B
- Financial periodFY2025
- RevenueCNY 1.17B
- Revenue growth-9.3%
- Net income-CNY 675.46M
- Free cash flow-CNY 171.39M
- Gross margin65.2%
Valuation Snapshot
latest market cap is HKD 1.93B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 1.17B | -CNY 675.46M | -CNY 171.39M | 65.2% | -0.55 | CNY 342.58M | CNY 1.76B | CNY 2.76B |
| FY2024 | CNY 1.29B | -CNY 277.23M | -CNY 139.09M | 74.2% | -0.23 | CNY 494.27M | CNY 1.84B | CNY 3.37B |
| FY2023 | CNY 1.19B | -CNY 1.30B | -CNY 467.14M | 75.9% | -1.07 | CNY 583.14M | CNY 1.80B | CNY 3.64B |
| FY2022 | CNY 1.26B | -CNY 319.60M | -CNY 966.96M | 81.3% | -0.27 | CNY 635.18M | CNY 1.40B | CNY 4.96B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 1.93B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About AIM Vaccine Co., Ltd.
AIM Vaccine Co., Ltd. engages in the research and development, manufacture, and sale of vaccine products for human use in the People's Republic of China and internationally. The company's product pipeline includes tetravalent meningococcal conjugate vaccine, which is in phase IV clinical trial for meningococcal disease 13-Valent pneumonia conjugate and 23-valent pneumonia polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AIM Vaccine Co., Ltd.'s market cap?
AIM Vaccine Co., Ltd.'s market capitalization is HKD 1.93B.
What does AIM Vaccine Co., Ltd. do?
AIM Vaccine Co., Ltd. engages in the research and development, manufacture, and sale of vaccine products for human use in the People's Republic of China and internationally. The company's product pipeline includes tetravalent meningococcal conjugate vaccine, which is in phase IV clinical trial for meningococcal disease 13-Valent pneumonia conjugate and 23-valent pneumonia polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine that is in phase III clinical trial to treat COVID-19 infection.